drugset / Trial / NCT06503679
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
Phase 1
Completed
49 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.
Timeline
- Start
- 2024-07-16
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | LY4100511 | Unknown | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Repaglinide | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |
Indications
No indication recorded.